Clinical Trial Update: Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the safety of a herpes simplex vaccine candidate (gD2t) with MPL and its efficacy in preventing genital herpes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Herpes

Drugs mentioned

• gD2t vaccine with MPL (glycoprotein D2t vaccine with MPL adjuvant)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Simplex | Phase 3 | Status: COMPLETED